Market revenue in 2022 | USD 26.4 million |
Market revenue in 2030 | USD 82.0 million |
Growth rate | 15.2% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.05% in 2022. Horizon Databook has segmented the UAE cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Stem cell therapy is gaining popularity in the UAE. The development of the regenerative medicine industry is aided by certain trends in the UAE's healthcare sector. UAE is moving away from importing medicines & healthcare products and instead allocating funds to support local production of therapeutic & pharmaceutical goods.
Furthermore, the expansion of regenerative medicine in the country is fueled by cutting-edge biotherapies such as immunomodulation therapy, gene & cell therapies, and tissue engineering. For instance, in August 2020, Abu Dhabi Stem Cells Center collaborated with Pluristem Therapeutics, Inc. to develop regenerative medicine and cell therapies to treat severe diseases, including COVID-19.
Moreover, according to an article published in Khaleej Times, in November 2022, gene therapy was used to treat a child suffering from a rare genetic disorder. Dubai is becoming the destination of choice in the Middle East region for the treatment of genetic conditions through gene therapy. For instance, in October 2021, UAE-Novartis, involved in advancing cell and gene therapy, has been able to help patients facing the threat of developing blindness.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UAE cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account